Abstract
In previous research we examined the science base of US biotechnology utilizing several unique patent and scientific paper databases (McMillan et al., 2000). Our findings highlighted the importance of public science in this industry. In this current research effort, we extend that analysis to include the subsequent citations those biotechnology patents received. Our conclusions are that the reliance on public science is stable when adjusted for forward citations, but the impact of different funding sources does change when citation weights are added. The science policy implications of these findings and future research opportunities are discussed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
